{"id":827764,"date":"2025-03-19T21:48:40","date_gmt":"2025-03-20T01:48:40","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/optinose-cancels-fourth-quarter-and-full-year-2024-earnings-call\/"},"modified":"2025-03-19T21:48:40","modified_gmt":"2025-03-20T01:48:40","slug":"optinose-cancels-fourth-quarter-and-full-year-2024-earnings-call","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/optinose-cancels-fourth-quarter-and-full-year-2024-earnings-call\/","title":{"rendered":"Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">YARDLEY, Pa., March  19, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iXMwL6NHePAfetFRj96D-tilzkef9-gNhBuIyVPnY8siieT1gHYSrHg8Jd3oGbi-Q8rukRcyNBfYlxgSmy86kw==\" rel=\"nofollow\" target=\"_blank\">Optinose<\/a> (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the cancellation of its earnings conference call for the quarter and full year ended December 31, 2024 that had originally been scheduled for March 20, 2025 at 8:00 a.m. Eastern Time.<\/p>\n<p align=\"justify\">The call is being cancelled due to the announcement earlier today that Optinose has entered into a definitive agreement to be acquired by Paratek Pharmaceuticals, subject to shareholder and other customary closing conditions.<\/p>\n<p align=\"justify\">The Company now expects to report results for the three- and twelve-month periods ended December 31, 2024, in a timely manner.<\/p>\n<p>\n        <strong>About Optinose<\/strong><br \/>\n        <br \/>Optinose is a specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn more, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=M2_nplD2El-25pM3X1w2x2It-MS8umFTYG06cMJQWFc9HAmLoaK_W2pY8dTdCpmZkocs5hcJRsXgZ_3zd8LDNYjCs3vPHJKcbhf8bYpjbEA=\" rel=\"nofollow\" target=\"_blank\">www.optinose.com<\/a> or follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gy5-LZnH7BKlJg1Nug7ZZPg3liXuajtMXawAUEZbqBy_4KXOtJ__ETKxMDumwoPpI2nZ6OMjBHjdEczRmOe_pw==\" rel=\"nofollow\" target=\"_blank\">X<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LWfJ5vSPtJacuMSzE7nLUjYtD5W7qlh1M_bm7DpkqAxsl7orqxH6Ip3eJfYp4vVXZn22ATH_Gwe0CrIjBJKvp5JeRnyOrsiE_LiZriDnZmo=\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>\n        <strong>Optinose Investor Contact<\/strong><br \/>\n        <br \/>Jonathan Neely<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lRYwx33aND5eAJxWkWrVSgqlXtYo4Om-YzxVxYBdjzvhwrSsZv-xcpD6uGPvY4XDs44vtTtCjJsHBZk7wufCxLJGaHwIAt8RzFgDiDkp3LYaD_2ZnIkR_W_Y3yttiPgY\" rel=\"nofollow\" target=\"_blank\">jonathan.neely@optinose.com<\/a><br \/>267.521.0531<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NzczNyM2ODE1MjYzIzIwOTA2MTg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MGU2ZTgwODctNmY2NS00MmIzLWFiNzUtOThlYmYxMjE1YjM5LTExMDIxODktMjAyNS0wMy0yMC1lbg==\/tiny\/OptiNose-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) &#8212; Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the cancellation of its earnings conference call for the quarter and full year ended December 31, 2024 that had originally been scheduled for March 20, 2025 at 8:00 a.m. Eastern Time. The call is being cancelled due to the announcement earlier today that Optinose has entered into a definitive agreement to be acquired by Paratek Pharmaceuticals, subject to shareholder and other customary closing conditions. The Company now expects to report results for the three- and twelve-month periods ended December 31, 2024, in a timely manner. About Optinose Optinose is a specialty pharmaceutical &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/optinose-cancels-fourth-quarter-and-full-year-2024-earnings-call\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-827764","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/optinose-cancels-fourth-quarter-and-full-year-2024-earnings-call\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) &#8212; Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the cancellation of its earnings conference call for the quarter and full year ended December 31, 2024 that had originally been scheduled for March 20, 2025 at 8:00 a.m. Eastern Time. The call is being cancelled due to the announcement earlier today that Optinose has entered into a definitive agreement to be acquired by Paratek Pharmaceuticals, subject to shareholder and other customary closing conditions. The Company now expects to report results for the three- and twelve-month periods ended December 31, 2024, in a timely manner. About Optinose Optinose is a specialty pharmaceutical &hellip; Continue reading &quot;Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/optinose-cancels-fourth-quarter-and-full-year-2024-earnings-call\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-20T01:48:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NzczNyM2ODE1MjYzIzIwOTA2MTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/optinose-cancels-fourth-quarter-and-full-year-2024-earnings-call\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/optinose-cancels-fourth-quarter-and-full-year-2024-earnings-call\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call\",\"datePublished\":\"2025-03-20T01:48:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/optinose-cancels-fourth-quarter-and-full-year-2024-earnings-call\\\/\"},\"wordCount\":165,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/optinose-cancels-fourth-quarter-and-full-year-2024-earnings-call\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NzczNyM2ODE1MjYzIzIwOTA2MTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/optinose-cancels-fourth-quarter-and-full-year-2024-earnings-call\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/optinose-cancels-fourth-quarter-and-full-year-2024-earnings-call\\\/\",\"name\":\"Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/optinose-cancels-fourth-quarter-and-full-year-2024-earnings-call\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/optinose-cancels-fourth-quarter-and-full-year-2024-earnings-call\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NzczNyM2ODE1MjYzIzIwOTA2MTg=\",\"datePublished\":\"2025-03-20T01:48:40+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/optinose-cancels-fourth-quarter-and-full-year-2024-earnings-call\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/optinose-cancels-fourth-quarter-and-full-year-2024-earnings-call\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/optinose-cancels-fourth-quarter-and-full-year-2024-earnings-call\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NzczNyM2ODE1MjYzIzIwOTA2MTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NzczNyM2ODE1MjYzIzIwOTA2MTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/optinose-cancels-fourth-quarter-and-full-year-2024-earnings-call\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/optinose-cancels-fourth-quarter-and-full-year-2024-earnings-call\/","og_locale":"en_US","og_type":"article","og_title":"Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call - Market Newsdesk","og_description":"YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) &#8212; Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the cancellation of its earnings conference call for the quarter and full year ended December 31, 2024 that had originally been scheduled for March 20, 2025 at 8:00 a.m. Eastern Time. The call is being cancelled due to the announcement earlier today that Optinose has entered into a definitive agreement to be acquired by Paratek Pharmaceuticals, subject to shareholder and other customary closing conditions. The Company now expects to report results for the three- and twelve-month periods ended December 31, 2024, in a timely manner. About Optinose Optinose is a specialty pharmaceutical &hellip; Continue reading \"Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/optinose-cancels-fourth-quarter-and-full-year-2024-earnings-call\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-20T01:48:40+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NzczNyM2ODE1MjYzIzIwOTA2MTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/optinose-cancels-fourth-quarter-and-full-year-2024-earnings-call\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/optinose-cancels-fourth-quarter-and-full-year-2024-earnings-call\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call","datePublished":"2025-03-20T01:48:40+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/optinose-cancels-fourth-quarter-and-full-year-2024-earnings-call\/"},"wordCount":165,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/optinose-cancels-fourth-quarter-and-full-year-2024-earnings-call\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NzczNyM2ODE1MjYzIzIwOTA2MTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/optinose-cancels-fourth-quarter-and-full-year-2024-earnings-call\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/optinose-cancels-fourth-quarter-and-full-year-2024-earnings-call\/","name":"Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/optinose-cancels-fourth-quarter-and-full-year-2024-earnings-call\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/optinose-cancels-fourth-quarter-and-full-year-2024-earnings-call\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NzczNyM2ODE1MjYzIzIwOTA2MTg=","datePublished":"2025-03-20T01:48:40+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/optinose-cancels-fourth-quarter-and-full-year-2024-earnings-call\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/optinose-cancels-fourth-quarter-and-full-year-2024-earnings-call\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/optinose-cancels-fourth-quarter-and-full-year-2024-earnings-call\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NzczNyM2ODE1MjYzIzIwOTA2MTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NzczNyM2ODE1MjYzIzIwOTA2MTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/optinose-cancels-fourth-quarter-and-full-year-2024-earnings-call\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/827764","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=827764"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/827764\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=827764"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=827764"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=827764"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}